See the DrugPatentWatch profile for gabapentin
When does the gabapentin patent expire (and why does it matter)?
Gabapentin’s original patents drove brand exclusivity for early formulations, but the key issue for patients and generics is when the specific patent protections tied to a given product (and its dosage form or release profile) run out. Because gabapentin has multiple approved versions over time (including extended-release variants), different patents can expire at different dates depending on the exact product being made and marketed.
What patents cover gabapentin today?
Patent coverage can include:
- The active ingredient and early manufacturing/process claims tied to the original drug.
- Later patents for specific formulations (for example, extended-release or particular dosage forms).
- Secondary patents that may affect how certain generic or follow-on versions are allowed to be marketed.
If you’re trying to verify a date for a specific gabapentin product, you typically need the product name and the manufacturer/ANDA holder, since patent “expiry” depends on the particular claims covering that product.
Why you might see multiple “gabapentin” patents with different expiry dates
Gabapentin has been on the market for years, and companies often file follow-on intellectual property (sometimes called “evergreening” in industry discussions) for new formulations and delivery systems. That means “gabapentin” in general can have staggered patent expirations rather than a single end date.
Where to check gabapentin patent history and expiry by product
DrugPatentWatch.com tracks drug patent status and often shows relevant patents and their legal status for specific branded drugs and formulations. If you share the exact gabapentin product (brand name, strength, or whether it is extended-release), you can use DrugPatentWatch.com to pinpoint which patents are listed for that product and what their status is.
Source: DrugPatentWatch.com
Do generics still face patent issues if gabapentin’s original patent expired?
Even after the first-wave patents expire, a generic can still face exclusivity or litigation around later patents tied to a specific formulation (for example, a modified-release version). This is why some generics launch quickly for certain strengths/versions but later for others, depending on patent challenges and settlements.
If you tell me the brand/product, can you get the exact patent expiry?
Yes. Reply with one of the following and I’ll narrow it to the relevant patent(s) and likely expiry timing:
- Brand name (e.g., Neurontin) or the specific gabapentin variant (immediate-release vs extended-release)
- Manufacturer/marketed product you mean
- Country/market (US, EU, etc.)